Nintedanib is under clinical development by Avalyn Pharma and currently in Phase I for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease). According to GlobalData, Phase I drugs for Interstitial Lung Diseases (Diffuse Parenchymal Lung Disease) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nintedanib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Nintedanib overview

Nintedanib is under development for the treatment of idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung disease. It is administered by inhalation route. It targets receptor tyrosine kinases (RTKs) including fibroblast growth factor (FGFR 1, 2,3), platelet-derived growth factor receptor (PDGFRB alpha and beta), vascular endothelial growth factor receptor (VEGFR 1,2,3) and non-receptor tyrosine kinases (nRTKs) including Lck, Lyn and Src kinases.

Avalyn Pharma overview

Avalyn Pharma is a biopharma company which focuses on advanced therapies for the treatment of Idiopathic Pulmonary Fibrosis. Avalyn Pharma is headquartered in Seattle, Washington, the US.

For a complete picture of Nintedanib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.